Speaker illustration

Doctor Xiaoyan Li

Bristol Myers-Squibb, Princeton, NJ (United States of America)

Comparative effectiveness and safety between non-VKA oral anticoagulants in non-valvular atrial fibrillation patients with differential duration of treatment: an analysis of the ARISTOPHANES study

Event: ESC Congress 2019

Topic: Oral Anticoagulation

Session: Atrial fibrillation and oral anticoagulation 3

Thumbnail

Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants versus warfarin in non-valvular atrial fibrillation patients: the dose subgroup analysis of the ARISTOPHANES study

Event: ESC Congress 2018

Topic: Oral Anticoagulation

Session: Atrial fibrillation - Stroke prevention - General

Thumbnail

Comparisons of clinical and economic outcomes between non-VKA oral anticoagulants and warfarin among non-valvular atrial fibrillation patients: the ARISTOPHANES study

Event: ESC Congress 2018

Topic: Health Economics

Session: Health economics

Thumbnail

Comparisons of clinical and economic outcomes between non-VKA oral anticoagulants among non-valvular atrial fibrillation patients: the ARISTOPHANES study

Event: ESC Congress 2018

Topic: Health Economics

Session: Health economics

Thumbnail

Comparative effectiveness and safety between non-VKA oral anticoagulants in non-valvular atrial fibrillation patients: a dose subgroup analysis of the ARISTOPHANES study

Event: ESC Congress 2018

Topic: Oral Anticoagulation

Session: Atrial fibrillation - Stroke prevention

Thumbnail

Effectiveness and safety of standard and lower dose apixaban compared to warfarin in non-valvular atrial fibrillation patients: a propensity score matched analysis

Event: ESC Congress 2017

Topic: Atrial fibrillation (AF)

Session: Stroke prevention

Thumbnail

Effectiveness and safety of apixaban versus warfarin among high-risk subgroups of non-valvular atrial fibrillation patients: a propensity score matched analysis

Event: ESC Congress 2017

Topic: Atrial fibrillation (AF)

Session: Stroke prevention

Thumbnail

Potential impact of apixaban on hospital resource use in patients with venous thromboembolism

Event: ESC Congress 2016

Topic: Thrombosis and coagulation

Session: Antithrombotics in daily clinical practice

Thumbnail

Demographic and clinical characteristics associated with initiation of individual oral anticoagulants among patients with newly diagnosed venous thromboembolism

Event: ESC Congress 2016

Topic: Thrombosis and coagulation

Session: Thrombosis and coagulation

Thumbnail

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb